214117-50-7

Basic information

• Product Name: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE
• Synonyms: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE;4-(4-Bromophenyl)-1H-1,2,4-triazol-5(4H)-one;3H-1,2,4-Triazol-3-one, 4-(4-broMophenyl)-2,4-dihydro-;4-(4-bromophenyl)-2H-1,2,4-triazol-3(4H)-one;-1H-1,2,4-triazol-5(4H)
• CAS NO: 214117-50-7
• Molecular Formula: C₈H₆BrN₃O
• Molecular Weight: 240.06
• Mol File: 214117-50-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.78
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE(214117-50-7)
• EPA Substance Registry System: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE(214117-50-7)

Safety Data

• Hazardous Substances Data: 214117-50-7(Hazardous Substances Data)

Usage

General Description

4-(4-Bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one is a chemical compound that belongs to the class of triazolone derivatives. It is a yellow solid at room temperature and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE has been studied for its potential biological activities, including antifungal, antimicrobial, and antitumor properties. It is also known for its ability to inhibit certain enzymes and receptors, making it a valuable tool in drug discovery and development. 4-(4-Bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one is a versatile building block in organic chemistry with various potential applications in medicinal and agricultural fields.

Upstream product

• 2493-02-9 4-bromophenyl isocyanate 
• 624-84-0 formic acid hydrazide 
• 2646-26-6 4-(4-bromophenyl)semicarbazide 
• 463-52-5 formamidine 
• 3473-63-0 formamidine acetic acid 
• 6294-89-9 hydrazinecarboxylic acid methyl ester 
• 106-40-1 4-bromo-aniline 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 1312809-83-8 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one 
• 1365802-72-7 4-[4-(4-{[3,5-bis(trifluoromethyl)phenyl]amino}phthalazin-1-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1346235-36-6 C₁₅H₂₀BrN₅O 
• 1346235-56-0 1-(3-(4-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl) piperazin-1-yl)propyl)-4-(4-bromophenyl)-1H-1,2,4-triazol-5(4H)-one 
• 1346235-16-2 C₁₁H₁₁Br₂N₃O 
• 895135-85-0 C₁₈H₂₃BrN₄O₃ 
• 864932-42-3 4-(4-bromophenyl)-1-isopropyl-1H-1,2,4-triazol-5(4H)-one 
• 153896-47-0 (S)-2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 648416-96-0 2,4-dihydro-4-(4-bromophenyl)-2-[(2S,3R)-(3-hydroxy-2-butyl)]-3H-1,2,4-triazol-3-one 
• 214117-54-1 4-(4-Bromo-phenyl)-2-((S)-sec-butyl)-2,4-dihydro-[1,2,4]triazol-3-one 
• 214117-56-3 (2R,4S)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(2S,3R)-3-[(1,1-dimethylethyl)dimethylsiloxy-2-butyl]]-3H-1,2,4-triazol-3-one 
• 214117-52-9 2,4-dihydro-4-(4-bromophenyl)-2-[(2S,3R)-[3-(1,1-dimethylethyl)dimethylsiloxy]-but-2-yl]-3H-1,2,4-triazol-3-one 
• 199797-85-8 (2R,4S)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(2S,3R)-(3-hydroxy-2-butyl)]-3H-1,2,4-triazol-3-one 

Relevant articles and documents

NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Design and synthesis of novel triazole antifungal derivatives by structure-based bioisosterism

The incidence of life-threatening fungal infections is increasing dramatically. In an attempt to develop novel antifungal agents, our previously synthesized phenoxyalkylpiperazine triazole derivatives were used as lead structures for further optimization. By means of structure-based bioisosterism, triazolone was used as a new bioisostere of oxygen atom. This type of bioisosteric replacement can improve the water solubility without loss of hydrogen-bonding interaction with the target enzyme. A series of triazolone-containing triazoles were rationally designed and synthesized. As compared with fluconazole, several compounds showed higher antifungal activity with broader spectrum, suggesting their potential for further evaluations.

Total synthesis of (2R,4S,2′S,3′R)-hydroxyitraconazole: Implementations of a recycle protocol and a mild and safe phase-transfer reagent for preparation of the key chiral units

A convergent total synthesis of enantiomerically-pure (2R,4S,2′S, 3′R)-hydroxyitraconazole 1b is described. The left dioxolane portion of the molecule was prepared in good yield by the conversion of (S)-10 to the corresponding enantiomerically and diastereomerically-pure acetonide (2R,4R)-3 by a recycle protocol involving diastereoselective crystallization of the tosylate salt, followed by re-equilibration of the mother liquor and crystallization. The right-hand triazolone moeity (2S,3R)-4 was generated by alkyaltion of triazolone 6 with enantiomerically pure cyclic sulfate (4R,5R)-7 under mild and essentially non-hazardous reaction conditions (TDA-1, K 2CO3, acetonitrile).